Frontiers in Pharmacology | Pharmacology of Anti-Cancer Drugs

Case Report

Published on 16 Feb 2026

Stage IIIB ROS1-Positive NSCLC management: crizotinib + surgery + TCM achieves exceptionally prolonged PFS (a case report)

in Pharmacology of Anti-Cancer Drugs

Yu Zhu
Hao Zhang
Zheng-xiang Han
Xu Zhu
Wan-ting Wang
Huai-yang Li
Shudong Zhu
Wei Shao

Frontiers in Pharmacology

doi 10.3389/fphar.2026.1693269

157 views

Original Research

Accepted on 13 Feb 2026

Extracellular Vesicles Delivering TIMP-2 Modulate MMP-1, MMP-2, and MMP-9 Expression in Human Lung Adenocarcinoma A549 cells

in Pharmacology of Anti-Cancer Drugs

Agnieszka Stawarska
Magdalena Bamburowicz-Klimkowska
Maciej Małecki
Anna M. Nowicka
Żaneta Słyk
Agata Kowalczyk
Alicja Targonska
Ireneusz P. Grudzinski

Frontiers in Pharmacology

Original Research

Published on 13 Feb 2026

Effect of the antifungal drug ciclopirox on the inhibition of HMGA2-mediated oncogenic capacity in ACHN renal cell carcinoma

in Pharmacology of Anti-Cancer Drugs

Xujie Liu
Jiahao Su
Lingling Song
Qizhong Fu
Xuan Li
Junying Li
Ying Liu
Jingyi Liao

Frontiers in Pharmacology

doi 10.3389/fphar.2026.1723954

245 views

Original Research

Published on 13 Feb 2026

Comparison of maintenance with decitabine or chemotherapy in a real-world cohort of patients with acute myeloid leukemia

in Pharmacology of Anti-Cancer Drugs

Zhi-Feng Wei
Jia-Qi Yan
Ye-Hui Tan
Hai Lin
Qiu-Ju Liu
Xiao-Liang Liu
Long Su
Su-Jun Gao

Frontiers in Pharmacology

doi 10.3389/fphar.2026.1753030

482 views

Review

Published on 13 Feb 2026

Ferroptosis and cuproptosis in head and neck squamous cell carcinoma: interconnected mechanisms and therapeutic implications

in Pharmacology of Anti-Cancer Drugs

Yinan Liu
Yanru Li

Frontiers in Pharmacology

doi 10.3389/fphar.2026.1694895

236 views

Original Research

Published on 12 Feb 2026

ACT001 synergizes with temozolomide-based chemoradiotherapy to cure refractory glioblastoma by targeting TNF-CXCL10-CD8+ T-cell immunity

in Pharmacology of Anti-Cancer Drugs

Ya Shu
Ze-hua Ding
Pan-pan Gao
Qi An
Li-qin Wu
Xin-ran Zhang
Hai-feng Jiang
Cheng Miao
Mei-ting Peng
Xiao-qian Chen

Frontiers in Pharmacology

doi 10.3389/fphar.2026.1745656

718 views

Systematic Review

Published on 12 Feb 2026

Cluster of differentiation 38 monoclonal antibody therapy in the treatment of multiple myeloma: a systematic review and meta-analysis

in Pharmacology of Anti-Cancer Drugs

Yan-Jun Guo
Zhi-Zhong Tian
Xiao-Fen Zhang
Zhen-Jun Zhu

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1687718

439 views

Original Research

Published on 12 Feb 2026

Clinical efficacy and safety of icaritin in patients with hepatocellular carcinoma: a real-world study

in Pharmacology of Anti-Cancer Drugs

Jingchang He
Lanlan Zhuang
Yi Lei
Biao Wang
Huaiyu Chen
Shuai Kang
Dingli Liu
Kunyuan Wang
Wenxuan Yu
Yuchen Lu

Frontiers in Pharmacology

doi 10.3389/fphar.2026.1677794

259 views

Original Research

Accepted on 11 Feb 2026

Double-edged-sword effect of bisphosphonates on the osteogenic differentiation of human periodontal ligament stem cells

in Pharmacology of Anti-Cancer Drugs

Mengyu Li
Jiajia Wang
Hanjin Ruan
Zhouyang Wang
Shaoyi Wang
Yue He
Zhiyuan Zhang

Frontiers in Pharmacology

Perspective

Published on 11 Feb 2026

Yttrium-90 radioembolization as an in vivo immune modulator: clinical evidence and pharmacologic implications

in Pharmacology of Anti-Cancer Drugs

Shiwei Tang
Jia Cai
Pandi Wu
Guanwu Wang

Frontiers in Pharmacology

doi 10.3389/fphar.2026.1770097

283 views

Original Research

Published on 11 Feb 2026

AUM-302, a novel triple PIM/PI3K/mTOR inhibitor, synergizes with RAS inhibition and impedes the growth of pancreatic ductal adenocarcinoma spheroids and organoids

in Pharmacology of Anti-Cancer Drugs

Emma Wen
Catalina Vera
Sahaana Kesavan
Fatim Kouassi
Joseph F. LaComb
Neecki Zand
David A. Tuveson
Amber N. Habowski
Antonio T. Baines
Agnieszka B. Bialkowska

Frontiers in Pharmacology

doi 10.3389/fphar.2026.1685433

489 views

Brief Research Report

Accepted on 09 Feb 2026

Effectiveness and safety of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma

in Pharmacology of Anti-Cancer Drugs

Gabriele Roccuzzo
Eleonora Bongiovanni
Giovanni Actis-Giorgetto
Chiara Astrua
Matteo Giovanni Brizio
Giovanni Cavaliere
Paolo Fava
SIMONE RIBERO
Pietro Quaglino

Frontiers in Pharmacology

Original Research

Accepted on 09 Feb 2026

A Retrospective Analysis of Outpatient Use of Small-Molecule Targeted Inhibitors for Lymphoma Across Six Regions of China (2016–2022)

in Pharmacology of Anti-Cancer Drugs

Chen Bo
Liying Chen
Ping Chen
王晨
Chang-Wei Yang
Yan Hu
Ran Wei
Liu-Cheng Li
Zhen-Lin Fu

Frontiers in Pharmacology

Review

Accepted on 09 Feb 2026

Epigenetic and Mitoepigenetic Regulation in Cancer and Therapeutic Perspectives

in Pharmacology of Anti-Cancer Drugs

Selcen Celik Uzuner
Ihsan Nalkiran
Ugur Uzuner
Hatice Sevim Nalkiran

Frontiers in Pharmacology

111 views

Review

Accepted on 09 Feb 2026

Epithelial-mesenchymal transition and sunitinib resistance in Renal Cell Carcinoma: mechanisms and therapeutic strategies

in Pharmacology of Anti-Cancer Drugs

Mingkai Zhang
Yirui Zhang
Fan Shen
Maoli Yan
Pengfei Cheng
Jing Teng
Mengqin Zou
Wendi Yao
Zhifeng Wang
Wen Li

Frontiers in Pharmacology

Original Research

Accepted on 09 Feb 2026

Targeting the NSUN2–DHODH Axis Reverses Ferroptosis Resistance and Oxaliplatin Resistance in Colorectal Cancer

in Pharmacology of Anti-Cancer Drugs

Junyi Zhang
Junxiao Shen
Tangye Zeng
Chang Gao
Biao Sheng
Junliang Li
Weiqi Zeng
Jieyi Shen
Chong Shen
Jiaojiao Wang

Frontiers in Pharmacology

Review

Published on 09 Feb 2026

Piezo1 as a mechanical checkpoint in T cell immunotherapy for solid tumors

in Pharmacology of Anti-Cancer Drugs

Xinmu Cui
Jianan Zhao
Huajie Tian

Frontiers in Pharmacology

doi 10.3389/fphar.2026.1722027

356 views

Original Research

Published on 09 Feb 2026

Targeted lipidomics meets transcriptomics: how cinobufagin rewires fatty acid, sphingolipid, and glycerophospholipid metabolism to combat hepatoma cell growth

in Pharmacology of Anti-Cancer Drugs

Wanjun Shao
Congying Yu
Rufei Xu
Xiaoqian Rong
Ailin Yang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1664915

381 views

Original Research

Published on 09 Feb 2026

Tumour microenvironment and HER2-low status dictate response and resistance to anthracycline-taxane chemotherapy in premenopausal TNBC: a retrospective multicohort study

in Pharmacology of Anti-Cancer Drugs

Shuanglong Cai
Shaohong Yu
Quan Zhou
Fangyuan Kuang
Lingyan Rao
Zhen Fang
Xiaoxin Zheng
Yong Shi
Jingdan Li

Frontiers in Pharmacology

doi 10.3389/fphar.2026.1752328

295 views

Mini Review

Published on 06 Feb 2026

Heart failure induced by cancer therapies: focus on targeted agents, mechanisms, risk prediction, and clinical management

in Pharmacology of Anti-Cancer Drugs

Lifeng Xiao
Xiaoluan Lin
Zhining Yang
Baihan Lin
Renxian Xie

Frontiers in Pharmacology

doi 10.3389/fphar.2026.1766603

422 views

Original Research

Published on 06 Feb 2026

Exploratory analysis of the association between body composition albumin-bound paclitaxel induced peripheral neuropathy

in Pharmacology of Anti-Cancer Drugs

Ying Jiang
Jiayuan Guo
Juan Zhao
Feng Chen
Jixiang Hou
Xiaorong Li
Zhenhao Li
Gaowa Jin
Quanfu Li

Frontiers in Pharmacology

doi 10.3389/fphar.2026.1644444

379 views

Correction

Accepted on 05 Feb 2026

Correction: Potential role of lactylation in intrinsic immune pathways in lung cancer

in Pharmacology of Anti-Cancer Drugs

Mengdie Huang
Ye Jin
Dandan Zhao
Xingren Liu

Frontiers in Pharmacology

Editorial

Published on 05 Feb 2026

Editorial: Plant bioactive compounds as modulators of oncogenic signalling pathways in cervical cancer

in Pharmacology of Anti-Cancer Drugs

Pratibha Pandey
Arif Hussain
Fahad Khan

Frontiers in Pharmacology

doi 10.3389/fphar.2026.1788689

377 views

Mini Review

Published on 04 Feb 2026

Immunotherapy-related cardiovascular toxicity: from mechanisms to management

in Pharmacology of Anti-Cancer Drugs

Lifeng Xiao
Weitong Liu
Yanchen Ji
Qiufeng Li
Junqing Pan
Renxian Xie

Frontiers in Pharmacology

doi 10.3389/fphar.2026.1762011

453 views

3,142 articles

articles

Stage IIIB ROS1-Positive NSCLC management: crizotinib + surgery + TCM achieves exceptionally prolonged PFS (a case report)

Extracellular Vesicles Delivering TIMP-2 Modulate MMP-1, MMP-2, and MMP-9 Expression in Human Lung Adenocarcinoma A549 cells

Effect of the antifungal drug ciclopirox on the inhibition of HMGA2-mediated oncogenic capacity in ACHN renal cell carcinoma

Comparison of maintenance with decitabine or chemotherapy in a real-world cohort of patients with acute myeloid leukemia

Ferroptosis and cuproptosis in head and neck squamous cell carcinoma: interconnected mechanisms and therapeutic implications

ACT001 synergizes with temozolomide-based chemoradiotherapy to cure refractory glioblastoma by targeting TNF-CXCL10-CD8+ T-cell immunity

Cluster of differentiation 38 monoclonal antibody therapy in the treatment of multiple myeloma: a systematic review and meta-analysis

Clinical efficacy and safety of icaritin in patients with hepatocellular carcinoma: a real-world study

Double-edged-sword effect of bisphosphonates on the osteogenic differentiation of human periodontal ligament stem cells

Yttrium-90 radioembolization as an in vivo immune modulator: clinical evidence and pharmacologic implications

AUM-302, a novel triple PIM/PI3K/mTOR inhibitor, synergizes with RAS inhibition and impedes the growth of pancreatic ductal adenocarcinoma spheroids and organoids

Effectiveness and safety of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma

A Retrospective Analysis of Outpatient Use of Small-Molecule Targeted Inhibitors for Lymphoma Across Six Regions of China (2016–2022)

Epigenetic and Mitoepigenetic Regulation in Cancer and Therapeutic Perspectives

Epithelial-mesenchymal transition and sunitinib resistance in Renal Cell Carcinoma: mechanisms and therapeutic strategies

Targeting the NSUN2–DHODH Axis Reverses Ferroptosis Resistance and Oxaliplatin Resistance in Colorectal Cancer

Piezo1 as a mechanical checkpoint in T cell immunotherapy for solid tumors

Targeted lipidomics meets transcriptomics: how cinobufagin rewires fatty acid, sphingolipid, and glycerophospholipid metabolism to combat hepatoma cell growth

Tumour microenvironment and HER2-low status dictate response and resistance to anthracycline-taxane chemotherapy in premenopausal TNBC: a retrospective multicohort study

Heart failure induced by cancer therapies: focus on targeted agents, mechanisms, risk prediction, and clinical management

Exploratory analysis of the association between body composition albumin-bound paclitaxel induced peripheral neuropathy

Correction: Potential role of lactylation in intrinsic immune pathways in lung cancer

Editorial: Plant bioactive compounds as modulators of oncogenic signalling pathways in cervical cancer

Immunotherapy-related cardiovascular toxicity: from mechanisms to management